Oncotelic Therapeutics Reports Material Agreement and Equity Sales
Ticker: OTLC · Form: 8-K · Filed: Aug 12, 2025 · CIK: 908259
| Field | Detail |
|---|---|
| Company | Oncotelic Therapeutics, Inc. (OTLC) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $20,000, $0.01, $100 million, $10 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Oncotelic inked a deal, took on debt, and sold stock on Aug 6th.
AI Summary
On August 6, 2025, Oncotelic Therapeutics, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unregistered sales of equity securities. This filing details these significant events for the company.
Why It Matters
This filing indicates significant financial activities, including new obligations and equity transactions, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Oncotelic Therapeutics, Inc. (company) — Registrant
- August 6, 2025 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Oncotelic Therapeutics, Inc. enter into?
The filing states that Oncotelic Therapeutics, Inc. entered into a material definitive agreement on August 6, 2025, but does not specify the nature of the agreement in the provided text.
What are the details of the direct financial obligation created by Oncotelic Therapeutics, Inc.?
The filing indicates the creation of a direct financial obligation by Oncotelic Therapeutics, Inc. on August 6, 2025, but the specific terms and amount are not detailed in the provided text.
What was the nature of the unregistered sales of equity securities by Oncotelic Therapeutics, Inc.?
The filing reports unregistered sales of equity securities by Oncotelic Therapeutics, Inc. on August 6, 2025, but the specifics of these sales are not elaborated upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 6, 2025.
What is the state of incorporation for Oncotelic Therapeutics, Inc.?
Oncotelic Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 887 words · 4 min read · ~3 pages · Grade level 11.7 · Accepted 2025-08-12 16:16:18
Key Financial Figures
- $20,000 — Jefferson has agreed to be compensated $20,000 per month in cash and issued 20,320,930
- $0.01 — common stock of the Company, par value $0.01 ("Common Stock") and Valor has agreed t
- $100 million — Company's market capitalization exceeds $100 million on any single trading day's close, the
- $10 million — se, the cumulative increase of at least $10 million in shareholder equity from the start of
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex10-1.htm (EX-10.1) — 182KB
- ex10-2.htm (EX-10.2) — 175KB
- 0001641172-25-023189.txt ( ) — 623KB
- otlc-20250806.xsd (EX-101.SCH) — 3KB
- otlc-20250806_lab.xml (EX-101.LAB) — 33KB
- otlc-20250806_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01, above
Item 1.01, above. Item 3.02 Unregistered Sale of Equity Securities. See
01, above
Item 1.01, above. Item 9.01 Financial (d) Exhibits. Exhibit No. Description Incorporation by reference 10.1 Jefferson Independent Contractor Agreement Filed herewith 10.2 Valor Independent Contractor Agreement Filed herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Oncotelic Therapeutics, Inc. Date: August 12, 2025 /s/ Vuong Trieu By: Vuong Trieu Chief Executive Officer -3-